Welcome to our dedicated page for Amarin Plc news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.
Amarin Corporation Plc (NASDAQ: AMRN) is a pioneering biopharmaceutical company dedicated to improving cardiovascular health through the development and commercialization of innovative therapeutic products. The company's flagship product, VASCEPA® (icosapent ethyl), is designed to address cardiovascular risks and has received FDA approval in the United States as well as marketing authorization in Europe under the brand name VAZKEPA®.
Amarin's mission is to advance scientific understanding and provide effective treatments for high-risk cardiovascular patients who have not adequately responded to traditional therapies. VASCEPA, a unique form of eicosapentaenoic acid (EPA), has been shown in clinical trials to significantly reduce cardiovascular events, offering a new therapeutic option for patients with elevated triglyceride levels.
In recent years, Amarin has undertaken strategic initiatives to bolster its market presence and financial stability. Notable accomplishments include:
- Leadership Restructure: In 2023, Amarin appointed new executives, including President & CEO Patrick Holt, to drive the company's global strategy and operational improvements.
- Revenue Growth in Europe: Amarin reported approximately 65% growth in in-market sales in Europe for Q1 2024 compared to Q4 2023, with significant progress in Spain and the UK.
- Financial Discipline: The company has implemented measures to reduce operating expenses and preserve cash, closing 2023 with $321 million in cash and no debt.
- Share Repurchase Plan: In early 2024, Amarin announced a share repurchase plan of up to $50 million to enhance shareholder value, pending necessary approvals.
Amarin's commitment to cardiovascular health extends globally, with operations in the United States, Europe, and partnerships in Canada, China, and other regions. The company continues to explore new market opportunities and strengthen its intellectual property portfolio, as evidenced by the recent extension of VAZKEPA's patent protection in Europe until 2039.
For more information, visit www.amarincorp.com and the dedicated VASCEPA site at www.vascepa.com.
Amarin (NASDAQ:AMRN) announced upcoming presentations of new REDUCE-IT trial subanalysis and mechanistic data at the American Heart Association's Scientific Sessions (November 16-18, 2024) in Chicago. The presentations will focus on VASCEPA®/VAZKEPA® (icosapent ethyl) effectiveness in patients with and without coronary artery disease (CAD) history.
Key presentations include cardiovascular risk reduction data in patients with prior cardiovascular events, EPA's antioxidant effects in endothelial cells, and EPA's impact on Lp(a) particle oxidation. The research highlights that approximately 20% of the global population is affected by high Lp(a) concentrations, which increase cardiovascular event risk by 2-4 times.
Amarin (AMRN) reported Q3 2024 financial results with total net revenue of $42.3 million, down 36% from $66.1 million in Q3 2023. The company maintains a strong cash position of $306 million. European VAZKEPA sales grew 19% sequentially, driven by Spain and UK markets. U.S. net product revenue was $30.6 million, while European and RoW revenues were $4.3 million and $6.9 million respectively. The company reported a net loss of $25.1 million or $0.06 per share. Operating expenses decreased 18% to $41.4 million due to cost optimization efforts.
Amarin plc (NASDAQ:AMRN) has announced two upcoming investor events. The first event is the Third Quarter 2024 Financial Results report on October 30, 2024, followed by a conference call with senior management at 5:00 pm ET. Investors can access the live call through the company's website or by dialing in.
The second event is a Virtual Analyst & Investor Day on November 14, 2024, from 8:00 AM to 10:00 AM EST. This event will focus on updating the investment community about the VASCEPA/VAZKEPA franchise, with emphasis on key geographies representing the franchise's future value, including Europe. The event will include a Q&A session with questions submitted in advance. Both events will be webcast and archived for future reference.
Amarin (NASDAQ: AMRN) announced the presentation of new research on VASCEPA (icosapent ethyl) at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting, September 9-13, 2024, in Madrid, Spain. The research highlights VASCEPA's impact in patients with diabetes and high cardiovascular risk, and the anti-Lp(a) oxidation effects of EPA. Two abstracts will be presented: a post-hoc analysis from the REDUCE-IT trial on patients with cardiovascular disease and diabetes who had coronary artery bypass grafting (CABG), and an in-vitro analysis of EPA's effects on lipoprotein(a) oxidation under hyperglycemic conditions. These findings aim to better understand therapies for reducing cardiovascular risk in vulnerable patients. Presentations are scheduled for September 10 and 11, 2024.
Amarin plc (NASDAQ:AMRN) announced new data presentations at the European Society of Cardiology (ESC) Congress from August 30 to September 2, 2024. The presentations focus on VASCEPA®/VAZKEPA® (icosapent ethyl) and its active ingredient, eicosapentaenoic acid (EPA). Key presentations include:
1. A REDUCE-IT® subgroup analysis on the effect of icosapent ethyl on cardiovascular events based on baseline small dense LDL cholesterol levels.
2. An examination of triglycerides' association with cardiovascular events in acute coronary syndrome patients.
3. An estimate of Spanish hospital patients eligible for icosapent ethyl treatment.
4. A study on EPA's effects on Lp(a) oxidation under high glucose conditions.
These presentations aim to enhance understanding of VASCEPA/VAZKEPA's clinical utility and mechanism of action in reducing residual cardiovascular risk.
Amarin plc (NASDAQ:AMRN) reported Q2 2024 financial results and provided a business update. Key highlights include:
- Total net revenue of $67.5 million, down 16% year-over-year
- Cash position of $307 million
- Net income of $1.5 million, or $0.00 per share
- Non-GAAP adjusted net income of $5.9 million, or $0.01 per share
- Completed CEO transition with Aaron Berg appointed as President and CEO
- Received regulatory approval for VASCEPA in China for cardiovascular risk reduction
- Secured national reimbursement for VAZKEPA in Portugal and Greece
- Delivered $50 million in annual savings from 2023 restructuring
The company faces challenges from generic competition in the U.S. but continues to focus on operational execution and expanding VASCEPA/VAZKEPA globally.
Amarin plc (NASDAQ:AMRN) has announced that the Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national reimbursement. This approval is aimed at reducing cardiovascular event risks in adult statin-treated patients with high cardiovascular risk, elevated triglycerides, and established cardiovascular disease or diabetes with at least one other cardiovascular risk factor.
The reimbursement, effective August 1, 2024, marks the eighth national reimbursement of VAZKEPA® in Europe, where Amarin has intellectual property protection until 2039. This approval addresses a significant need in Portugal, where cardiovascular disease accounts for 29% of total mortality. Amarin's CEO, Aaron Berg, emphasized the importance of this new treatment option for Portuguese patients and physicians.
Amarin plc (NASDAQ:AMRN) has announced it will host a conference call on July 31, 2024, at 8:00 a.m. ET to discuss its second quarter 2024 financial results. The call will feature Aaron Berg, President & CEO, and other senior management team members. The financial results will be released pre-market on the same day.
To enhance shareholder engagement, Amarin is partnering with Say Technologies, allowing shareholders to submit and upvote questions from July 17th at 8:00 am ET until 24 hours before the call. Selected questions will be answered during the earnings call. Shareholders can submit questions at https://app.saytechnologies.com/amarin-2024-q2.
The conference call can be accessed through Amarin's website or by dialing in. A replay will be available after the call.
Amarin 's (NASDAQ:AMRN) partner, EddingPharm, has received regulatory approval for VASCEPA® (icosapent ethyl) from China's National Medical Products Administration (NMPA) for cardiovascular risk reduction. VASCEPA will now be used alongside statin therapy to reduce cardiovascular events in adults with elevated triglycerides (≥150 mg/dL) and other high-risk factors. EddingPharm is preparing for the National Reimbursement Drug Listing (NRDL) to enhance commercial launch across Mainland China. This approval is significant given China's high cardiovascular disease (CVD) burden, with 330 million patients and CVD accounting for up to 47% of deaths. VASCEPA's inclusion in the NRDL could ensure widespread access and reimbursement. Additionally, Amarin will receive a $15 million milestone payment and tiered double-digit royalties on net sales in China. However, EddingPharm must conduct a post-approval study to further validate VASCEPA's efficacy.
Amarin (NASDAQ:AMRN) has appointed Aaron Berg as the new President and CEO, effective immediately. Berg, previously Executive Vice President and President of the U.S. Business at Amarin, succeeds Patrick Holt, who is stepping down to pursue other opportunities. Berg brings over 30 years of biopharmaceutical industry experience, including significant roles at Kos Pharmaceuticals and Essentialis. His immediate focus will be on delivering value to investors and maximizing the potential of VASCEPA®/VAZKEPA for patients. This leadership change is expected to drive strategic initiatives and business growth for Amarin.
FAQ
What is the current stock price of Amarin Plc (AMRN)?
What is the market cap of Amarin Plc (AMRN)?
What does Amarin Corporation do?
What is VASCEPA®?
How did Amarin perform financially in recent quarters?
What recent strategic initiatives has Amarin undertaken?
What are the key markets for Amarin's products?
What recent achievements have boosted Amarin's market position?
How does VASCEPA® benefit patients?
Who are the key executives at Amarin?
What is the purpose of Amarin's share repurchase plan?
How does Amarin support its global operations?
